Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc
Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.
Core Technology and Treatment Solutions
The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.
Business Model and Revenue Generation
Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.
Market Position and Industry Significance
Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.
Operational Focus and Customer Base
The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.
Clinical Impact and Safety
At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.
Competitive Landscape and Differentiation
Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.
Conclusion
In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.
Sensus Healthcare (Nasdaq: SRTS) has signed an exclusive U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its FDA-cleared TransDermal Infusion System, a non-invasive drug delivery technology. Beginning immediately, Sensus will market this system to dermatologists for various applications, such as skin rejuvenation and pre- and post-plastic surgery treatments. The system allows for the painless delivery of drugs like Botox and hyaluronic acid, enhancing patient care and offering a competitive edge in the aesthetic dermatology field.
Sensus Healthcare (SRTS) reported a strong third quarter for 2021, achieving revenues of $5.5 million, a 244% increase from $1.6 million in Q3 2020. This marks the company’s first profitable quarter, with a net income of $0.2 million or $0.01 per diluted share, improving from a net loss of $(1.7) million a year prior. The company shipped 14 systems during the quarter and reaffirmed expectations for continued growth and profitability into Q4 and 2021. Cash reserves stood at $16.4 million with no long-term debt.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 4, 2021, at 4:30 p.m. Eastern time to discuss its third quarter 2021 financial results. Management will provide a business update and discuss recent and upcoming milestones. Investors can access the call by dialing 800-285-6670 (U.S.) or 832-553-9961 (International), and the call will also be available via live webcast. Following the call, a replay will be accessible via telephone and online. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.
Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.
Sensus Healthcare (Nasdaq: SRTS) announces participation in the upcoming Fall Clinical Dermatology Conference from October 21-24, 2021, in Las Vegas. Over 1,200 physicians are registered to attend this first major in-person dermatology event in 18 months. Key opinion leaders will present on superficial radiation therapy (SRT) for non-melanoma skin cancer. CEO Joe Sardano emphasizes strong sales momentum for the second half of 2021, driven by favorable reimbursement changes and a backlog of orders. Sensus anticipates achieving profitability this year.
Sensus Healthcare (Nasdaq: SRTS), based in Boca Raton, Fla., will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13 to 15, 2021. CEO Joe Sardano's presentation will be accessible via a webcast starting at 7:00 am (EST) on September 13. Sensus Healthcare specializes in non-invasive treatments for both oncological and non-oncological conditions, featuring technologies like the Sculptura™ and SRT-100™ systems, aimed at enhancing patient quality of life.
Sensus Healthcare (SRTS) reported Q2 2021 revenues of $5.4 million, a 358% increase year-over-year and 77% sequentially. The net loss narrowed to $(0.3) million or $(0.02) per share, improving from $(2.6) million or $(0.16) per share in Q2 2020. The company shipped 17 systems, enhancing its installed base to 515 systems. Cash stood at $15.2 million with no long-term debt. Management expressed optimism for continued growth, aided by new reimbursement schedules and an expanded international strategy, particularly in China and India.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 5, 2021, at 4:30 p.m. Eastern to discuss its Q2 2021 financial results and provide business updates. The call will be accessible via dial-in numbers and a live webcast. Sensus is focused on non-invasive medical treatments for various conditions, including its Sculptura™ and SRT systems for cancer treatment and skin conditions. This call aims to communicate recent achievements and future milestones.
Sensus Healthcare (Nasdaq: SRTS), a leader in non-invasive medical devices, announced management's participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. The conference will facilitate one-on-one virtual meetings with investors. Sensus specializes in innovative treatments for oncological and non-oncological conditions, including the Sculptura™ system for radiation therapy and SRT-100™ for treating skin cancers. The company's focus is on enhancing patient quality of life through advanced technologies.